USA - NASDAQ:ZYME - US98985Y1082 - Common Stock
The current stock price of ZYME is 16.25 USD. In the past month the price increased by 12.93%. In the past year, price increased by 24.14%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 21.01 | 393.01B | ||
AMGN | AMGEN INC | 13.09 | 153.65B | ||
GILD | GILEAD SCIENCES INC | 14.74 | 141.56B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 22.62 | 98.23B | ||
REGN | REGENERON PHARMACEUTICALS | 12.97 | 62.75B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.45B | ||
ARGX | ARGENX SE - ADR | 79.48 | 45.09B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.84 | 39.75B | ||
INSM | INSMED INC | N/A | 30.60B | ||
NTRA | NATERA INC | N/A | 24.86B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.13B | ||
BIIB | BIOGEN INC | 8.9 | 20.89B |
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company is headquartered in Middletown, Delaware and currently employs 273 full-time employees. The company went IPO on 2019-06-24. The firm is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The firm engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. The company has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. The company is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The firm has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
ZYMEWORKS INC
108 Patriot Drive, Suite A
Middletown DELAWARE V6H 3V9 US
CEO: Ali Tehrani
Employees: 273
Phone: 13022748744
The current stock price of ZYME is 16.25 USD. The price decreased by -1.46% in the last trading session.
The exchange symbol of ZYMEWORKS INC is ZYME and it is listed on the Nasdaq exchange.
ZYME stock is listed on the Nasdaq exchange.
15 analysts have analysed ZYME and the average price target is 22.5 USD. This implies a price increase of 38.44% is expected in the next year compared to the current price of 16.25. Check the ZYMEWORKS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ZYMEWORKS INC (ZYME) has a market capitalization of 1.22B USD. This makes ZYME a Small Cap stock.
ZYMEWORKS INC (ZYME) currently has 273 employees.
ZYMEWORKS INC (ZYME) has a support level at 14.31. Check the full technical report for a detailed analysis of ZYME support and resistance levels.
The Revenue of ZYMEWORKS INC (ZYME) is expected to grow by 71.6% in the next year. Check the estimates tab for more information on the ZYME EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ZYME does not pay a dividend.
ZYMEWORKS INC (ZYME) will report earnings on 2025-10-29.
ZYMEWORKS INC (ZYME) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.97).
The outstanding short interest for ZYMEWORKS INC (ZYME) is 9.4% of its float. Check the ownership tab for more information on the ZYME short interest.
ChartMill assigns a technical rating of 9 / 10 to ZYME. When comparing the yearly performance of all stocks, ZYME is one of the better performing stocks in the market, outperforming 82.85% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to ZYME. No worries on liquidiy or solvency for ZYME as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months ZYME reported a non-GAAP Earnings per Share(EPS) of -0.97. The EPS increased by 25.38% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -18.04% | ||
ROE | -22.03% | ||
Debt/Equity | 0 |
15 analysts have analysed ZYME and the average price target is 22.5 USD. This implies a price increase of 38.44% is expected in the next year compared to the current price of 16.25.
For the next year, analysts expect an EPS growth of 29.92% and a revenue growth 71.6% for ZYME